Abstract:Aldose Reductase (AR) reduces a variety of substrates, such as aldehydes, aldoses and corticosteroids. It is the first and rate-limiting enzyme of the polyol pathway and is an important target enzyme for diabetes-associated complications, including retinopathy, neuropathy, and nephropathy. Inhibitors targeting this enzyme are structurally different and some of them have side effects. In existing publications, computational techniques are applied to investigate the binding affinities of existing inhibitors and predicting the affinities of newly designed ligands. However, these calculations only employ coarse and approximated methods such as docking and MM/PBSA. Brute force simulations are employed to study the dynamics of the system but no converged statistics is obtained. As a result, these computations provide results not consistent with experimental values and large discrepancies exist. In the current work, we employ the enhanced sampling technique of alchemical free energy simulation to calculate the binding affinities of several ligands targeting AR. The statistical error is defined with care and the correlation in the time-series data is fully considered. The statistically optimal estimators are used to extract the free energy estimates and the predicted results are in agreement with the experimental values. Less computationally demanding end-point free energy methods are also performed to compare their efficiency with the alchemical methods. As is expected, the end-point methods are of less accuracy and reliability compared with the alchemical free energy methods. The decomposition of the free energy difference in each alchemical transformation into the enthalpic and entropic components gives further insights on the thermodynamics. The enthalpy-entropy compensation is observed in this case. As the structural data obtained from experiments are only snapshots and more details are needed to understand the dynamics of the protein-ligand system, the conformational ensemble is analyzed. We identify important residues involved in the protein-ligand binding case and short-lived interactions formed due to fluctuations in the conformational ensemble. The current work shed light on the atomic detailed understanding of the dynamics of AR-inhibitors interactions.

Inhibitor Selectivity Between Aldo – Keto Reductase Superfamily Members AKR 1 B 10 and AKR 1 B 1 : Role of Trp 112 ( Trp 111 )

Aldo-Keto Reductase Family 1 Member B10 Inhibitors: Potential Drugs for Cancer Treatment

Crystal Structure of Perakine Reductase, Founding Member of A Novel Aldo-Keto Reductase (akr) Subfamily That Undergoes Unique Conformational Changes During Nadph Binding

Switching the Chemoselectivity of Perakine Reductase for Selective Reduction of Α,β-Unsaturated Ketones by Arg127 Mutation.

Development of Biaryl-Containing Aldo-Keto Reductase 1C3 (AKR1C3) Inhibitors for Reversing AKR1C3-Mediated Drug Resistance in Cancer Treatment

Synthesis and biological evaluation of steroidal derivatives as selective inhibitors of AKR1B10

Aldo–Keto Reductase AKR1C1–AKR1C4: Functions, Regulation, and Intervention for Anti-cancer Therapy

Structural and Mutational Studies on an Aldo-Keto Reductase AKR5C3 from Gluconobacter Oxydans.

Overview of human 20 alpha-hydroxysteroid dehydrogenase (AKR1C1): Functions, regulation, and structural insights of inhibitors

A three-level regulatory mechanism of the aldo-keto reductase subfamily AKR12D

Overview of AKR1C3: Inhibitor Achievements and Disease Insights.

Development of highly potent and specific AKR1C3 inhibitors to restore the chemosensitivity of drug-resistant breast cancer

Structural‐guided design to improve the catalytic performance of aldo‐keto reductase KdAKR

Aldo-keto reductases 7A subfamily: A mini review

In silico study of novel alpha tocopheroids as effective inhibitors of aldo-keto reductase 1c3 (AKR1C3) enzyme

Tolrestat acts atypically as a competitive inhibitor of the thermostable aldo-keto reductase Tm1743 from Thermotoga maritima

Catalytic characteristics of AKR1C1-AKR1C4 and AKR1C9 on oxymesterone

Understanding Aldose Reductase-Inhibitors interactions with free energy simulation

Semirational engineering of an aldo–keto reductase Km AKR for overcoming trade‐offs between catalytic activity and thermostability

Discovery of an Aldo-Keto reductase 1C3 (AKR1C3) degrader

Rational Design of Dehydrogenase/Reductases Based on Comparative Structural Analysis of Prereaction-State and Free-State Simulations for Efficient Asymmetric Reduction of Bulky Aryl Ketones